To enhance prognostic accuracy, we took an innovative approach by combining preoperative PNI—identified as the most effective marker among nutritional and immune indices—with traditional tumor markers (CEA, CA19‐9, NSE, and CYFRA21‐1) in predicting postoperative recurrence for IB‐stage NSCLC. This evidence concerns the gene ENO2 and non-small cell lung carcinoma.